Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 20 of 20 results for aflibercept

  1. Ranibizumab for treating choroidal neovascularisation associated with pathological myopia (TA298)

    Evidence-based recommendations on ranibizumab (Lucentis) for treating choroidal neovascularisation associated with pathological myopia in adults.

    Technology appraisal guidance
    Published
    27 November 2013
    View recommendations

    Sections for TA298

  2. Aflibercept solution for injection for treating wet age‑related macular degeneration (TA294)

    Evidence-based recommendations on aflibercept solution for injection (Eylea) for treating wet age-related macular degeneration in adults.

    Technology appraisal guidance
    Published
    24 July 2013
    View recommendations

    Sections for TA294

  3. High-dose aflibercept for treating wet age-related macular degeneration TS ID 10590

      Status ...

    Technology appraisal guidance
    Topic selection

  4. Aflibercept for untreated diabetic macular oedema TS ID 10621

      Status ...

    Technology appraisal guidance
    Topic selection

  5. Faricimab for treating macular oedema caused by retinal vein occlusion [ID6197]

    In development [GID-TA11148] Expected publication date: 14 August 2024

    Technology appraisal guidance
    In development